Back to Results
First PageMeta Content
Pharmaceutical Benefits Scheme / Pharmacology / Myelofibrosis / International Prognostic Scoring System / IPSS / Clinical trial / Medicine / Health / Ruxolitinib


PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer
Add to Reading List

Document Date: 2015-03-12 23:53:04


Open Document

File Size: 349,88 KB

Share Result on Facebook
UPDATE